Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholera Vaccines | 19 | 2019 | 19 | 4.960 |
Why?
|
| Typhoid Fever | 17 | 2019 | 19 | 4.710 |
Why?
|
| Cholera | 21 | 2019 | 21 | 4.430 |
Why?
|
| Diarrhea | 19 | 2019 | 56 | 3.940 |
Why?
|
| Escherichia coli Infections | 14 | 2019 | 37 | 3.400 |
Why?
|
| Escherichia coli Vaccines | 8 | 2019 | 10 | 2.590 |
Why?
|
| Dysentery, Bacillary | 8 | 2019 | 12 | 2.220 |
Why?
|
| Enterotoxigenic Escherichia coli | 8 | 2019 | 15 | 1.970 |
Why?
|
| Shigella Vaccines | 5 | 2019 | 5 | 1.900 |
Why?
|
| Child, Preschool | 45 | 2019 | 1167 | 1.870 |
Why?
|
| Infant | 41 | 2019 | 969 | 1.770 |
Why?
|
| Vaccination | 10 | 2016 | 123 | 1.760 |
Why?
|
| Child | 45 | 2019 | 2219 | 1.710 |
Why?
|
| Hepatitis E | 4 | 2018 | 6 | 1.700 |
Why?
|
| Salmonella Infections | 9 | 2018 | 11 | 1.680 |
Why?
|
| Developing Countries | 8 | 2019 | 43 | 1.550 |
Why?
|
| Adolescent | 42 | 2019 | 3255 | 1.490 |
Why?
|
| Disease Outbreaks | 7 | 2018 | 35 | 1.480 |
Why?
|
| Antibodies, Bacterial | 6 | 2019 | 31 | 1.360 |
Why?
|
| Mass Vaccination | 5 | 2016 | 7 | 1.320 |
Why?
|
| Influenza, Human | 7 | 2014 | 122 | 1.220 |
Why?
|
| Humans | 88 | 2019 | 29123 | 1.210 |
Why?
|
| Models, Theoretical | 3 | 2018 | 126 | 1.110 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 5 | 2019 | 6 | 1.100 |
Why?
|
| Shigella | 5 | 2019 | 7 | 1.030 |
Why?
|
| Immunity, Herd | 4 | 2019 | 5 | 1.030 |
Why?
|
| Fever | 7 | 2018 | 56 | 0.980 |
Why?
|
| Young Adult | 28 | 2019 | 2402 | 0.960 |
Why?
|
| India | 13 | 2018 | 61 | 0.930 |
Why?
|
| Administration, Oral | 14 | 2019 | 169 | 0.920 |
Why?
|
| Population Surveillance | 8 | 2014 | 119 | 0.870 |
Why?
|
| Bacterial Vaccines | 2 | 2012 | 7 | 0.830 |
Why?
|
| Female | 49 | 2019 | 18173 | 0.830 |
Why?
|
| Paratyphoid Fever | 2 | 2019 | 3 | 0.810 |
Why?
|
| Adult | 34 | 2019 | 8426 | 0.800 |
Why?
|
| Salmonella | 3 | 2018 | 3 | 0.790 |
Why?
|
| Vibrio cholerae | 3 | 2015 | 3 | 0.790 |
Why?
|
| Male | 46 | 2019 | 17815 | 0.740 |
Why?
|
| Viral Vaccines | 2 | 2011 | 13 | 0.730 |
Why?
|
| Escherichia coli | 5 | 2014 | 82 | 0.730 |
Why?
|
| Salmonella typhi | 9 | 2018 | 10 | 0.730 |
Why?
|
| Incidence | 12 | 2018 | 1119 | 0.700 |
Why?
|
| Vaccines, Conjugate | 4 | 2019 | 15 | 0.670 |
Why?
|
| Sanitation | 1 | 2018 | 3 | 0.660 |
Why?
|
| Hygiene | 1 | 2018 | 13 | 0.660 |
Why?
|
| Rotavirus Infections | 4 | 2019 | 11 | 0.650 |
Why?
|
| Mortality | 2 | 2019 | 109 | 0.610 |
Why?
|
| Enteritis | 2 | 2019 | 5 | 0.580 |
Why?
|
| Encephalitis, Japanese | 3 | 2015 | 3 | 0.580 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 863 | 0.570 |
Why?
|
| Immunization, Secondary | 2 | 2016 | 9 | 0.570 |
Why?
|
| Rural Population | 8 | 2016 | 246 | 0.570 |
Why?
|
| Environmental Monitoring | 2 | 2013 | 26 | 0.540 |
Why?
|
| Vaccines, Inactivated | 9 | 2018 | 37 | 0.540 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2012 | 11 | 0.530 |
Why?
|
| Water Supply | 1 | 2014 | 10 | 0.510 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2014 | 3 | 0.510 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 49 | 0.510 |
Why?
|
| Diarrhea, Infantile | 1 | 2014 | 6 | 0.510 |
Why?
|
| Intestinal Perforation | 1 | 2014 | 9 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 8 | 2016 | 285 | 0.470 |
Why?
|
| Salmonella enterica | 4 | 2016 | 5 | 0.460 |
Why?
|
| Cause of Death | 1 | 2014 | 220 | 0.450 |
Why?
|
| Length of Stay | 1 | 2014 | 292 | 0.440 |
Why?
|
| Egypt | 12 | 2014 | 16 | 0.430 |
Why?
|
| Neisseria meningitidis, Serogroup A | 1 | 2012 | 1 | 0.430 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 298 | 0.420 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 33 | 0.410 |
Why?
|
| Residence Characteristics | 2 | 2016 | 181 | 0.410 |
Why?
|
| Africa South of the Sahara | 8 | 2018 | 20 | 0.400 |
Why?
|
| Infant, Newborn | 14 | 2019 | 599 | 0.380 |
Why?
|
| Feces | 6 | 2019 | 29 | 0.380 |
Why?
|
| Double-Blind Method | 7 | 2018 | 503 | 0.380 |
Why?
|
| Cambodia | 8 | 2014 | 8 | 0.370 |
Why?
|
| Bacteremia | 3 | 2016 | 53 | 0.370 |
Why?
|
| Bacterial Infections | 2 | 2012 | 42 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2018 | 152 | 0.370 |
Why?
|
| Campylobacter Infections | 2 | 2008 | 6 | 0.360 |
Why?
|
| Measles | 1 | 2009 | 3 | 0.350 |
Why?
|
| Immunization | 2 | 2019 | 28 | 0.350 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 9 | 0.340 |
Why?
|
| Tanzania | 9 | 2015 | 12 | 0.340 |
Why?
|
| Congresses as Topic | 2 | 2019 | 37 | 0.330 |
Why?
|
| Malaria | 4 | 2016 | 10 | 0.310 |
Why?
|
| Urban Population | 3 | 2017 | 79 | 0.300 |
Why?
|
| Ciprofloxacin | 3 | 2016 | 12 | 0.300 |
Why?
|
| Cost of Illness | 3 | 2018 | 63 | 0.290 |
Why?
|
| Prevalence | 6 | 2016 | 898 | 0.290 |
Why?
|
| Middle Aged | 12 | 2018 | 10834 | 0.290 |
Why?
|
| Family Characteristics | 2 | 2017 | 32 | 0.280 |
Why?
|
| Risk Factors | 5 | 2018 | 3537 | 0.270 |
Why?
|
| Cohort Studies | 8 | 2019 | 1688 | 0.260 |
Why?
|
| Databases, Factual | 2 | 2016 | 332 | 0.250 |
Why?
|
| Japanese Encephalitis Vaccines | 2 | 2015 | 2 | 0.250 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 55 | 0.250 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 391 | 0.240 |
Why?
|
| Bangladesh | 6 | 2019 | 7 | 0.240 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 38 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2016 | 15 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 154 | 0.220 |
Why?
|
| Immunization Schedule | 3 | 2019 | 24 | 0.200 |
Why?
|
| Nepal | 3 | 2014 | 9 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2015 | 859 | 0.190 |
Why?
|
| Escherichia coli Proteins | 3 | 2005 | 31 | 0.180 |
Why?
|
| Rotavirus Vaccines | 1 | 2019 | 7 | 0.180 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 18 | 0.180 |
Why?
|
| Geographic Information Systems | 1 | 2019 | 14 | 0.180 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 532 | 0.180 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1362 | 0.180 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 30 | 0.180 |
Why?
|
| Growth Disorders | 1 | 2019 | 4 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 159 | 0.170 |
Why?
|
| Pregnant Women | 1 | 2018 | 5 | 0.170 |
Why?
|
| Hepatitis Antibodies | 1 | 2018 | 1 | 0.170 |
Why?
|
| Jaundice | 1 | 2018 | 4 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3101 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 980 | 0.160 |
Why?
|
| Macaca mulatta | 1 | 2019 | 322 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 38 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 2 | 2014 | 9 | 0.150 |
Why?
|
| Africa | 2 | 2014 | 23 | 0.150 |
Why?
|
| Hepatitis E virus | 2 | 2014 | 3 | 0.150 |
Why?
|
| Pregnancy | 3 | 2017 | 815 | 0.150 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 8 | 0.150 |
Why?
|
| Vietnam | 2 | 2014 | 23 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2014 | 27 | 0.150 |
Why?
|
| Washington | 1 | 2016 | 7 | 0.150 |
Why?
|
| Milk, Human | 1 | 2017 | 14 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2016 | 55 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 3719 | 0.150 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 29 | 0.150 |
Why?
|
| Geography | 2 | 2014 | 34 | 0.150 |
Why?
|
| Education | 1 | 2016 | 30 | 0.150 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2014 | 3 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 52 | 0.140 |
Why?
|
| Endemic Diseases | 1 | 2016 | 4 | 0.140 |
Why?
|
| World Health Organization | 2 | 2014 | 15 | 0.140 |
Why?
|
| Uganda | 1 | 2016 | 7 | 0.140 |
Why?
|
| Indonesia | 1 | 2016 | 7 | 0.140 |
Why?
|
| Nigeria | 1 | 2016 | 17 | 0.140 |
Why?
|
| Enterotoxins | 3 | 2005 | 6 | 0.140 |
Why?
|
| Bacterial Toxins | 3 | 2005 | 16 | 0.140 |
Why?
|
| Immunity, Mucosal | 1 | 2016 | 5 | 0.140 |
Why?
|
| Poliovirus | 1 | 2016 | 3 | 0.140 |
Why?
|
| Antibody-Producing Cells | 1 | 2016 | 3 | 0.140 |
Why?
|
| Database Management Systems | 1 | 2016 | 11 | 0.140 |
Why?
|
| Hospitalization | 2 | 2016 | 417 | 0.140 |
Why?
|
| Public Health | 2 | 2014 | 73 | 0.140 |
Why?
|
| Aged | 6 | 2016 | 9492 | 0.140 |
Why?
|
| Salmonella paratyphi A | 2 | 2013 | 2 | 0.130 |
Why?
|
| Immunoglobulin A | 4 | 2019 | 9 | 0.130 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 69 | 0.130 |
Why?
|
| Mice | 2 | 2019 | 2370 | 0.130 |
Why?
|
| Research Design | 2 | 2015 | 286 | 0.130 |
Why?
|
| Haemophilus Vaccines | 1 | 2015 | 1 | 0.130 |
Why?
|
| Bacterial Capsules | 1 | 2015 | 5 | 0.130 |
Why?
|
| Haemophilus Infections | 1 | 2015 | 7 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 721 | 0.130 |
Why?
|
| Immunoglobulin G | 4 | 2019 | 104 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2015 | 61 | 0.130 |
Why?
|
| Genotype | 2 | 2014 | 735 | 0.130 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 15 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 248 | 0.120 |
Why?
|
| Animals | 5 | 2019 | 7299 | 0.120 |
Why?
|
| Phenotype | 2 | 2014 | 629 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2014 | 68 | 0.120 |
Why?
|
| Salmonella Vaccines | 1 | 2013 | 1 | 0.120 |
Why?
|
| Internationality | 1 | 2013 | 21 | 0.120 |
Why?
|
| Population Density | 1 | 2013 | 6 | 0.120 |
Why?
|
| Educational Status | 1 | 2014 | 164 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 464 | 0.110 |
Why?
|
| Republic of Korea | 1 | 2012 | 8 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2013 | 163 | 0.110 |
Why?
|
| Computers, Handheld | 1 | 2012 | 7 | 0.110 |
Why?
|
| Niger | 1 | 2012 | 1 | 0.110 |
Why?
|
| Dengue | 1 | 2012 | 4 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 142 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 31 | 0.100 |
Why?
|
| Sex Factors | 1 | 2014 | 631 | 0.100 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 22 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 726 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 163 | 0.100 |
Why?
|
| Vibrio cholerae O1 | 3 | 2015 | 3 | 0.100 |
Why?
|
| Rotavirus | 1 | 2010 | 4 | 0.100 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 14 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 231 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 326 | 0.090 |
Why?
|
| Fluoroquinolones | 1 | 2009 | 10 | 0.090 |
Why?
|
| Asia | 3 | 2013 | 17 | 0.090 |
Why?
|
| Gangliosides | 1 | 2008 | 6 | 0.090 |
Why?
|
| Indian Ocean Islands | 3 | 2013 | 3 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2013 | 128 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2017 | 2021 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2014 | 3112 | 0.080 |
Why?
|
| Azithromycin | 2 | 2004 | 14 | 0.080 |
Why?
|
| Hospitals | 3 | 2012 | 89 | 0.070 |
Why?
|
| Survival Rate | 1 | 2009 | 795 | 0.070 |
Why?
|
| Vaccines, Subunit | 2 | 2016 | 3 | 0.070 |
Why?
|
| Ghana | 2 | 2016 | 22 | 0.070 |
Why?
|
| Seasons | 1 | 2006 | 84 | 0.070 |
Why?
|
| Cryptosporidiosis | 1 | 2005 | 2 | 0.070 |
Why?
|
| Cryptosporidium parvum | 1 | 2005 | 2 | 0.070 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2005 | 1 | 0.070 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2005 | 1 | 0.070 |
Why?
|
| Granuloma | 1 | 2005 | 13 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2005 | 51 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2005 | 30 | 0.060 |
Why?
|
| Placebos | 2 | 2015 | 61 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2016 | 153 | 0.060 |
Why?
|
| Campylobacter coli | 1 | 2003 | 2 | 0.060 |
Why?
|
| Campylobacter jejuni | 1 | 2003 | 3 | 0.060 |
Why?
|
| Probability | 3 | 2012 | 150 | 0.060 |
Why?
|
| Age Factors | 2 | 2016 | 1108 | 0.050 |
Why?
|
| Cholera Toxin | 1 | 2002 | 5 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 709 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 51 | 0.050 |
Why?
|
| Serotyping | 2 | 2016 | 14 | 0.050 |
Why?
|
| Bacteria | 2 | 2012 | 45 | 0.050 |
Why?
|
| Prognosis | 3 | 2016 | 1362 | 0.050 |
Why?
|
| Shigella sonnei | 1 | 2019 | 1 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2019 | 11 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2019 | 15 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 23 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 16 | 0.040 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 22 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 198 | 0.040 |
Why?
|
| Vaccines, Combined | 1 | 2017 | 3 | 0.040 |
Why?
|
| Lactation | 1 | 2017 | 14 | 0.040 |
Why?
|
| Guinea-Bissau | 1 | 2016 | 1 | 0.040 |
Why?
|
| Senegal | 1 | 2016 | 1 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 20 | 0.040 |
Why?
|
| Clinical Audit | 1 | 2016 | 1 | 0.040 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2016 | 3 | 0.040 |
Why?
|
| Poliomyelitis | 1 | 2016 | 4 | 0.040 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2016 | 3 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 17 | 0.030 |
Why?
|
| Weights and Measures | 1 | 2015 | 3 | 0.030 |
Why?
|
| Anthropometry | 1 | 2016 | 82 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 49 | 0.030 |
Why?
|
| Ethiopia | 1 | 2015 | 1 | 0.030 |
Why?
|
| Vibrio cholerae O139 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Democratic People's Republic of Korea | 1 | 2015 | 1 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 64 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 454 | 0.030 |
Why?
|
| Fimbriae Proteins | 2 | 2005 | 5 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2014 | 3 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 25 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 48 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 68 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 865 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 30 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2013 | 4 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2012 | 2 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 3 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2012 | 26 | 0.030 |
Why?
|
| Communication | 1 | 2014 | 122 | 0.030 |
Why?
|
| Health Policy | 1 | 2012 | 80 | 0.030 |
Why?
|
| Hantavirus | 1 | 2012 | 1 | 0.030 |
Why?
|
| Orientia tsutsugamushi | 1 | 2012 | 1 | 0.030 |
Why?
|
| Rickettsia | 1 | 2012 | 3 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 469 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 21 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 289 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2012 | 24 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2012 | 31 | 0.030 |
Why?
|
| Decision Making | 1 | 2014 | 180 | 0.030 |
Why?
|
| Models, Biological | 1 | 2013 | 373 | 0.030 |
Why?
|
| Acute Disease | 1 | 2012 | 239 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 263 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2010 | 11 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cough | 1 | 2010 | 19 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 2001 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2013 | 224 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 787 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 930 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2005 | 8 | 0.020 |
Why?
|
| Virulence | 1 | 2004 | 19 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 186 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2005 | 77 | 0.020 |
Why?
|
| Erythromycin | 1 | 2003 | 6 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 637 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 727 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 207 | 0.010 |
Why?
|
| Pediatrics | 1 | 2003 | 132 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2002 | 39 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 641 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 1306 | 0.010 |
Why?
|